KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Receivables (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Receivables for 17 consecutive years, with $472.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables rose 1.48% to $472.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $472.5 million, a 1.48% increase, with the full-year FY2025 number at $472.5 million, up 1.48% from a year prior.
  • Receivables was $472.5 million for Q4 2025 at Bio-Rad Laboratories, roughly flat from $474.2 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $513.1 million in Q1 2023 to a low of $401.2 million in Q2 2021.
  • A 5-year average of $461.5 million and a median of $467.1 million in 2023 define the central range for Receivables.
  • Peak YoY movement for Receivables: grew 18.91% in 2022, then decreased 10.42% in 2024.
  • Bio-Rad Laboratories' Receivables stood at $425.7 million in 2021, then grew by 18.91% to $506.2 million in 2022, then fell by 1.06% to $500.9 million in 2023, then decreased by 7.05% to $465.6 million in 2024, then increased by 1.48% to $472.5 million in 2025.
  • Per Business Quant, the three most recent readings for BIO's Receivables are $472.5 million (Q4 2025), $474.2 million (Q3 2025), and $478.0 million (Q2 2025).